SCHEMBL2650840

SCHEMBL2650840

O=C(O)Cc1ccc(SC2CCOCC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.42
CAMK2A Q9UQM7 1/20 0.42
AKR1B1 P15121 1/20 0.40
ABCC4 O15439 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
PTGS1 P23219 1/20 0.40
HTT P42858 1/20 0.40
CYP26A1 O43174 1/20 0.39
RHEB Q15382 1/20 0.39
HNF4A P41235 1/20 0.38
GSTP1 P09211 1/20 0.37
GSTM2 P28161 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
FFAR1 O14842 1/20 0.37
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1107504 0.89 CA2 (0.48) CA2CAMK2AAKR1B1ABCC4LMNA
SCHEMBL2651655 0.85 CA2 (0.46) CA2CAMK2AAKR1B1ABCC4LMNA
SCHEMBL9071834 0.80 LIPE (0.48) LMNAGAATSHRKMT2AALDH1A1
SCHEMBL6275217 0.78 MAOA (0.33) RHEB
Hydrochloric Acid SCHEMBL1165090 0.75 CA2 (0.39) CA2CAMK2AAKR1B1ABCC4LMNA
Hydrochloric Acid SCHEMBL1165092 0.75 CA2 (0.39) CA2CAMK2AAKR1B1ABCC4LMNA
SCHEMBL4066853 0.74 HPGD (0.48) LMNATSHRRHEBKMT2AALDH1A1
SCHEMBL17147873 0.74 CARM1 (0.44) LMNAHTTALDH1A1HPGDHSD17B10
SCHEMBL2514621 0.74 ALDH1A1 (0.37) CA2CAMK2AAKR1B1ABCC4LMNA
SCHEMBL12593796 0.73 POLB (0.42) LMNACYP26A1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168962-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2010-03-31 EP disclosed
US-7214681-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2007-05-08 US disclosed
EP-1594867-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2005-11-16 EP disclosed
US-20040181067-A1 Tri(cyclo) substituted amide compounds OSI PHARMACEUTICALS, INC. 2004-09-16 US disclosed
WO-2004072031-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS PROSIDION LIMITED (GB) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181067-A1 Tri(cyclo) substituted amide compounds GPR119, IAPP, SLC5A1 CA2 1656/4885CAMK2A 1609/4885AKR1B1 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.